SCHEMBL4592116

SCHEMBL4592116

Cc1cccn(CC(=O)O)c1=O

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
ALDH1A1 P00352 3/20 0.49
KMT2A Q03164 3/20 0.49
MEN1 O00255 2/20 0.49
LMNA P02545 2/20 0.49
ALOX12 P18054 1/20 0.49
RECQL P46063 1/20 0.49
KDM4E B2RXH2 3/20 0.47
POLB P06746 1/20 0.47
PKM P14618 1/20 0.44
MMP8 P22894 1/20 0.39
MMP14 P50281 1/20 0.39
MMP17 Q9ULZ9 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
APEX1 P27695 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15030482 0.83 MEN1 (0.54) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL19847989 0.82 PKM (0.46) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL16918354 0.82 PARP1 (0.54) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL16806644 0.81 NPSR1 (0.46) PKM
SCHEMBL9609770 0.81 KDM4E (0.50) MAPTALDH1A1KMT2ALMNAKDM4E
SCHEMBL14221996 0.80 PARP1 (0.44) MAPTKMT2AMEN1KDM4EPKM
SCHEMBL2831481 0.80 ALDH1A1 (0.52) MAPTALDH1A1KMT2AMEN1LMNA
SCHEMBL2823548 0.80 MMP2 (0.45) ALDH1A1KMT2AKDM4EPKM
SCHEMBL17677701 0.80 PKM (0.40) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL5179205 0.79 EGLN1 (0.53) MAPTALDH1A1KMT2AMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3006437-B1 (+)-5-(3,4-DIFLUOROPHENYL)-5-[(3-METHYL-2-OXOPYRIDIN-1(2H)-YL)METHYL]IMIDAZOLIDINE-2,4-DIONE AND DRUG CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2020-08-05 EP disclosed
EP-2880033-B1 CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF PURDUE PHARMA LP (US) 2020-06-17 EP disclosed
WO-2018193387-A1 HETEROCYCLIC COMPOUNDS WITH MICROBIOCIDAL PROPERTIES PI INDUSTRIES LTD. (IN) 2018-10-25 WO disclosed
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof KAKEN PHARMACEUTICAL CO., LTD. (JP) 2018-06-19 US disclosed
US-9518041-B2 (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and drug containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-12-13 US disclosed
US-9518041-B2 (+)-5-(3,4-difluorophenyl)-5-[(3-methyl-2-oxopyridin-1(2H)-yl)methyl]imidazolidine-2,4-dione and drug containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-12-13 US disclosed
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 US disclosed
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-11-24 US disclosed
US-9447072-B2 Pyridone derivative and pharmaceutical containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2016-09-20 US disclosed
EP-3006029-A1 COMPOSITION FOR MAINTAINING PLATELET FUNCTION Kaken Pharmaceutical Co., Ltd. (JP) 2016-04-13 EP disclosed
US-9085561-B2 Cyclic urea- or lactam-substituted quinoxaline-type piperidines as ORL-1 modulators PURDUE PHARMA L.P. (US) 2015-07-21 US disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 US disclosed
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-18 US disclosed
WO-2013085016-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 WO disclosed
WO-2013085017-A1 PYRIDONE DERIVATIVE AND MEDICINE CONTAINING SAME 科研製薬株式会社 (JP) 2013-06-13 WO disclosed
CN-101287738-B Imidazo benzodiazepine derivatives HOFFMANN LA ROCHE 2011-08-10 CN disclosed
CN-101287738-A Imidazo benzodiazepine derivatives HOFFMANN LA ROCHE (CH) 2008-10-15 CN disclosed
EP-1937688-A1 IMIDAZO BENZODIAZEPINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-07-02 EP disclosed
WO-2007042421-A1 IMIDAZO BENZODIAZEPINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160340349-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO MAPT 2709/4885ALDH1A1 327/4885KMT2A 2609/4885
US-10000476-B2 Pyridone derivative, pharmaceutical containing the same and methods of use thereof PNPO, PDXK, PLPBP MAPT 3357/4885ALDH1A1 368/4885KMT2A 2495/4885
US-20150166506-A1 PYRIDONE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME PLPBP, PDXK, PNPO MAPT 2709/4885ALDH1A1 327/4885KMT2A 2609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.